Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX supplied by Immunine replaces the deficient protein in hemophilia B patients. Once infused, it participates in the intrinsic tenase complex, activating factor X to Xa, which then leads to thrombin generation and fibrin clot formation, correcting the coagulation defect.

The dose of Immunine is individualized by the prescribing clinician based on the patient’s baseline factor IX activity, the severity of bleeding, body weight, and the clinical situation (e.g., prophylaxis versus acute treatment). No fixed dosing regimen is provided in public information.

Safety data for Immunine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Immunine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Immunine belongs to the same therapeutic class as other factor IX concentrates, whether plasma‑derived or recombinant. All aim to restore factor IX activity, but differences may exist in manufacturing processes, viral inactivation methods, and immunogenicity profiles. Clinical choice depends on physician preference, patient history, and regulatory approvals.

Immunine must be stored at 2‑8 °C in a refrigerator, protected from light. It should not be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration and allow the solution to reach room temperature if required by the administration protocol.

Immunine is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and volume are determined by the prescribing clinician, who may adjust based on patient tolerance and factor IX activity levels measured during treatment.

The most serious risks include the development of inhibitory antibodies that neutralize factor IX activity, severe allergic or anaphylactic reactions, and rare thromboembolic events. Monitoring for these complications is essential, especially after repeated exposures.

Immunine is contraindicated in individuals with known hypersensitivity to human factor IX or any component of the formulation. Patients with a history of severe inhibitor development or uncontrolled thrombosis should also avoid its use unless specifically advised by a specialist.